Abstract

BackgroundPelvic nodal metastasis in prostate cancer impacts patient outcome negatively. ObjectiveTo explore tumor-infiltrating immune cells as a potential predictive tool for regional lymph node (LN) metastasis. Design, setting, and participantsWe applied multiplex immunofluorescence and targeted transcriptomic analysis on 94 radical prostatectomy specimens in patients with (LN+) or without (LN–) pelvic nodal metastases. Both intraepithelial and stromal infiltrations of immune cells and differentially expressed genes (mRNA and protein levels) were correlated with the nodal status. Outcome measurements and statistical analysisThe identified CD4 effector cell signature of nodal metastasis was validated in a comparable independent patient cohort of 184 informative cases. Patient outcome analysis and decision curve analysis were performed with the CD4 effector cell density–based signature. Results and limitationsIn the discovery cohort, both tumor epithelium and stroma from patients with nodal metastasis had significantly lower infiltration of multiple immune cell types, with stromal CD4 effector cells highlighted as the top candidate marker. Targeted gene expression analysis and confirmatory protein analysis revealed key alteration of extracellular matrix components in tumors with nodal metastasis. Of note, stromal CD4 immune cell density was a significant independent predictor of LN metastasis (odds ratio [OR] = 0.15, p = 0.004), and was further validated as a significant predictor of nodal metastasis in the validation cohort (OR = 0.26, p < 0.001). ConclusionsDecreased T-cell infiltrates in the primary tumor (particularly CD4 effector cells) are associated with a higher risk of LN metastasis. Future evaluation of CD4-based assays on prostate cancer diagnostic biopsy materials may improve selection of at-risk patients for the treatment of LN metastasis. Patient summaryIn this report, we found that cancer showing evidence of cancer metastasis to the lymph nodes tends to have less immune cells present within the tumor. We conclude that the extent of immune cells present within a prostate tumor can help doctors determine the most appropriate treatment plan for individual patients.

Highlights

  • Prostate cancer (PCa) is the second most prevalent cancer in men worldwide [1]

  • We identified a CD4 effector cell–based tumoral immune signature of lymph node (LN)+ disease, which was validated in a comparable independent patient cohort

  • To the best of our knowledge, this is the first study to have carried out a comprehensive analysis of the tumor immune infiltrates and the tumor transcriptome to investigate for potential associations with PCa pelvic nodal metastasis

Read more

Summary

Introduction

Prostate cancer (PCa) is the second most prevalent cancer in men worldwide [1]. During PCa progression, regional lymph nodes (LNs) are common sites for metastases. Objective: To explore tumor-infiltrating immune cells as a potential predictive tool for regional lymph node (LN) metastasis. Design, setting, and participants: We applied multiplex immunofluorescence and targeted transcriptomic analysis on 94 radical prostatectomy specimens in patients with (LN+) or without (LN–) pelvic nodal metastases. Both intraepithelial and stromal infiltrations of immune cells and differentially expressed genes (mRNA and protein levels) were correlated with the nodal status. Results and limitations: In the discovery cohort, both tumor epithelium and stroma from patients with nodal metastasis had significantly lower infiltration of multiple immune cell types, with stromal CD4 effector cells highlighted as the top candidate marker. Stromal CD4 immune cell density was a significant org/licenses/by-nc-nd/4.0/)

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call